Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!

Thoracic Surgery Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy; Oncology Unit, Monaldi Hospital, Naples, Italy; Oncology Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy; Pathology Unit, Federico II University of Naples, Italy; Pneumology Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy; Pathology Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy Correspondence to: Alfonso Fiorelli, MD, PhD. Thoracic Surgery Unit, Universitàdella Campania “Luigi Vanvitelli”, Piazza Miraglia, 2, I-80138 Naples, Italy. Email: alfonso.fiorelli@unicampania.it. Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Translational Medicine. The article did not undergo external peer review. Comment on: Liang W, Cai K, Chen C, et al. Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). Transl Lung Cancer Res 2019;8:1163-73.